Effects and Interactions of Naloxone and Amphetamine on Self-Stimulation of the Prefrontal Cortex and Dorsal Tegmentum

K B J FRANKLIN AND A ROBERTSON

Department of Psychology, McGill University, Montreal, Quebec, Canada

Received 14 March 1981

FRANKLIN, K B J AND A ROBERTSON Effects and interactions of naloxone and amphetamine on self-stimulation of the prefrontal cortex and dorsal tegmentum PHARMAC BIOCHEM BEHAV 16(3) 433-436, 1982 — Naloxone (0 1 to 10 mg/kg) caused a dose-dependent depression of self-stimulation of the medial prefrontal cortex (PFC), lateral hypothalamus (LH) and a region in the dorsal tegmentum lateral to the central gray (DT) The DT contains many enkephalin fibers and is a site for stimulation-produced analgesia, while the PFC contains little enkephalin and does not support stimulation-produced analgesia. However, self-stimulation rates of the PFC, DT and LH were all equally depressed by naloxone. In order to study possible opiate-dopamine interactions, we examined the effects of naloxone on the facilitatory effects of D- and L-amphetamine (1 0 mg/kg) on self-stimulation of the DT and PFC. If amphetamine mildly facilitated self-stimulation (L-amphetamine on DT self-stimulation and D-amphetamine on PFC self-stimulation), then the addition of naloxone was without effect. If amphetamine greatly increased self-stimulation (D-amphetamine on DT self-stimulation), naloxone caused a depression of the amphetamine effect. It is argued that naloxone's effects in this and other reports reviewed is related to the level of self-stimulation performance, and not to the level of enkephalin at the self-stimulation site, nor to amphetamine's effects on dopamine activity

Self-stimulation L-Amphetamine Reward Prefrontal cortex Naloxone Lateral hypothalamus D-Amphetamine Central gray

SINCE the discovery that the brain contains endogenous opiate-like peptides [10], there has been interest in the notion that opiate peptide neurons might be involved in the rewarding effects of opiates and natural rewards as well as in analgesia [1,18] If this were so, electrical stimulation of opiate-peptide neurons might be expected to be rewarding and this reward to be blocked by opiate antagonists. In this regard, Beluzzi and Stein reported that naloxone depresses self-stimulation (SS) of the enkephalin-rich periaqueductal gray, a site which was chosen because it yields analgesia when stimulated [2] However, other studies have reported no effect of naloxone on SS of the lateral hypothalamus and medial forebrain bundle [6, 9, 12, 20, 21] or caudate nucleus [20], the latter of which contains moderate levels of enkephalin and opiate receptors [3,17] More recently Stapelton et al [19] found mild (<30%) depression from naloxone in SS of the periaqueductal gray, lateral hypothalamus, substantia nigra and nucleus accumbens The SS sites that have been tested contain varying amounts of enkephalins and it is not clear whether the effectiveness of naloxone in reducing SS bears any relationship to the presence of enkephalin Moreover, enkephalins might influence SS indirectly via dopamine (DA) neurons which are thought to be presynaptically inhibited by enkephalin [11,15] If this were the case the effects of naloxone might be increased in conditions where DA activity is high such as during amphetamine-induced potentiation of SS [4,9]

The present study compared the effect of naloxone on SS in three sites the dorsal tegmentum, prefrontal cortex and lateral hypothalamus The dorsal tegmental region near the periaqueductal gray contains enkephalin [17] and, like previously tested periaqueductal gray sites [2], is a site for analgesia produced by electrical stimulation (F Abbott and R Melzack, personal communication) The medial prefrontal cortex (PFC) is thought to contain very low levels of enkephalin [3, 16, 17] and does not seem to support stimulation analgesia (Abbott and Melzack, personal communication) SS of the lateral hypothalamus (LH) was tested for comparison with other reports In addition, naloxone was tested on rats self-stimulating in the PFC and DT under the influence of a 1 mg/kg dose of D- or L-amphetamine This dose of D-amphetamine produces a facilitation of SS across all three sites [5] and the difference between the effects of the two isomers is maximal [14]

METHOD

Subjects

Subjects were 25 adult male Wistar rats which selfstimulated through bipolar stainless steel electrodes (Plastic Products, Roanoke, VA), 127 μ in diameter at each tip, implanted under Nembutal anaesthesia (60 mg/kg, IP) in the PFC (10 rats), the LH (7 rats) or the DT (8 rats) Electrode sites are shown in Fig 1




FIG 1 Locations of self-stimulation electrode tips shown on planes from the atlas of Pellegrino and Cushman [14] Numbers alongside each frame show the position in millimeters anterior (A) or posterior (P) to the ear bars

Apparatus and Pretraining

Following a one-week recovery period after the surgery, rats were trained to lever press for 0 2 sec trains of 100 Hz, 0 2 msec pulses of electrical stimulation in a test chamber $(30 \times 30 \times 30 \text{ cm})$ with a lever at one end, 6 cm above the floor Stimulation current was monitored on an oscilloscope

When a rat had learned to bar press for stimulation, the current was adjusted to twice that of the threshold for responding (to about 160 μ A for LH, 185 μ A for DT, and 400 μ A for PFC) and remained at that level for the duration of the experiment Rats were then trained to respond on a random interval 10 sec schedule of reinforcement in daily 90 min sessions. The number of presses was automatically recorded every 5 min. After 5 to 10 sessions on this regimen, response rates had stabilized (744 resp/hr for LH, 720 resp/hr for DT and 533 resp/hr for PFC). Drug tests were then begun

Drugs

D- and L-amphetamine sulphate were dissolved in

isotonic saline to a concentration of 1 0 mg/ml (expressed as the salt) Naloxone HCl was dissolved in isotonic saline to concentrations of 0 1, 1 0 and 10 mg/ml Both drugs were administered IP in a volume of 1 0 ml/kg

Testing Procedure

Rats were tested during 90 min sessions The first 25 min of the session were used to calculate baseline responding The drugs were injected between the 25th and 30th min of the session If both naloxone and amphetamine were administered, naloxone was always injected 2–3 min before amphetamine Response rates were then measured for the following 60 min A minimum of 3 days was allowed between successive drug sessions to avoid cumulative drug effects

All 3 groups of rats received naloxone in doses of 0 1, 1 0 or 10 0 mg/kg Only rats with DT or PFC electrodes received naloxone (1 0 or 10 0 mg/kg) in combination with D- or L-amphetamine (1 0 mg/kg)

Five rats with PFC electrodes and four rats with DT elec-




FIG 2 Self-stimulation responding after saline or naloxone (0 1, 1 0 or 10 mg/kg) given alone (left side of figure) or in combination with 1 0 mg/kg L- or D-amphetamine (middle and right side of figure) Electrodes were implanted in lateral hypothalamus (LH-top), medial prefrontal cortex (PFC-middle), or dorsal tegmentum (DT-bottom) Vertical bars represent standard errors, number above bars represent n per group

trodes and all seven rats with LH electrodes were also tested with another combination of drug treatments methysergide, a serotonin antagonist, alone and in combination with D- and L-amphetamine These data have been reported elsewhere [5] The additional drug treatments were delivered in different orders for each rat, and one week separated any tests with different drugs

Data Analysis

Response rates for the 60 min under a drug condition were expressed as a percentage of the baseline rates in the 25 min preceding drug administration The data were then analyzed by repeated measures design ANOVAS followed by Newman-Keuls tests for the comparisons of interest

RESULTS

Effects of Naloxone on SS

It can be seen in Fig 2 that naloxone administered alone depressed self-stimulation in a dose-dependent manner (naloxone main effect, F(3,51)=1057, p<00001), and that the amount of depression was very similar in the three sites In both control and drug sessions the response rate of PFC self-stimulators declined more than the rates of DT or LH self-stimulators so that the mean PFC rate over the last 60 min of the session was below the pre-injection baseline rate Because of this there was a significant main effect of site, F(2,17)=717, p<0006 However, there was no interaction between naloxone and site, F(6,51)=072, NS

Effects of D- and L-Amphetamine Alone and in Combination with Naloxone on SS

The effects of amphetamine alone depended on both isomer and the site of stimulation, F(1,16)=81, p<001That is, D-amphetamine facilitated PFC self-stimulation (p<005) but L-amphetamine did not D-amphetamine caused a 149% increase in self-stimulation of the DT (p<001) whereas L-amphetamine only produced a 20% increase (p<005)

There was a significant interaction of naloxone, amphetamine and site of stimulation, F(1,16)=57, p<003) Naloxone combined with D- or L-amphetamine did not significantly alter PFC response rates compared to the effects of D- or L-amphetamine alone Similarly, L-amphetamine combined with naloxone did not alter responding in DT rats compared with L-amphetamine alone However, naloxone (10 mg/kg) added to D-amphetamine in DT rats caused a suppression of the D-amphetamine effect (p<005)

DISCUSSION

Naloxone produced a dose dependent reduction in SS at all three sites tested This result is in agreement with some other reports that naloxone depresses self-stimulation [2,19] However naloxone was as effective in depressing SS of the PFC which contains little enkephalin as it was in the DT where there are many enkephalin fibers [17] A similar lack of reliable association between the presence of enkephalin in the SS site and the effects of naloxone on self-stimulation can be seen in comparing the results of previous studies Belluzzi and Stein [2] found that naloxone (1 and 10 mg/kg) severely (60%) depressed SS of the periaqueductal gray but Stapleton et al [19] found periaqueductal gray SS to be only mildly depressed (9%) by 10 mg/kg naloxone, less so than other sites such as the substantia nigra There is also no relationship between the effect of naloxone and sites for stimulation analgesia Self-stimulation of the dorsal tegmentum and periaqueductal gray, sites which support analgesia ([2,19], Abbott and Melzack, personal communication) is no more affected by naloxone than SS of the PFC or SN, which do not show analgesia ([19], Abbott and Melzack, personal communication)

Naloxone did not modify the effects of amphetamine in any simple way No effect of naloxone was seen when SS was mildly facilitated by L-amphetamine in DT selfstimulators or by D-amphetamine in PFC self-stimulators In these cases, the depressant effect of naloxone was antagonized by administration of amphetamine However, when SS of the DT was greatly increased by D-amphetamine, naloxone did reduce responding Thus the effect of naloxone on amphetamine facilitated SS seems to be related to the effectiveness of amphetamine in facilitating SS rather than to the DA releasing effect of the amphetamine isomers, in which D- is 2–5 times as potent as L-amphetamine [7,8] Similarly, Holtzman [9] found that naloxone was most effective against the dose of D-amphetamine which produced the maximum facilitation

In summary, naloxone seems to depress SS when sessions are long [19] or rewards are intermittent (this paper) but to have unreliable effects when brain stimulation rewards are frequent and strong enough to produce vigorous responding [9,20] The depression of SS can be overcome by amphetamine when amphetamine produces mild facilitation of responding but curiously re-appears when amphetamine ([9], this paper) or other facilitatory drugs [12] would increase SS to very high rates This pattern of results suggests that naloxone influences SS indirectly via opiate receptors in some system which primarily modulates performance of SS rather than the SS reward itself

ACKNOWLEDGEMENTS

This research was supported by Natural Sciences and Engineering Council Grant No A6303 to K Franklin and Grant No A66 to P M Milner Additional support was provided by the Stairs Memorial Fund of McGill University We thank Smith, Kline and French Canada Ltd for their gift of D- and L-amphetamine and Endo Laboratories for the gift of naloxone

REFERENCES

- 1 Belluzzi, J D, N Grant, V Garsky, D Sarantakis, C D Wise and L Stein Analgesia induced in vivo by central administration of enkephalin in rat Nature 260: 625-626, 1976
- 2 Beluzzi, J D and L Stein Enkephalins may mediate euphoria and drive reduction reward *Nature* 266 556-557, 1977
- 3 Elde, T, T Hokfelt, O Johansson and L Terenius Immunohistochemical studies using antibodies to leucineenkephalin initial observations on the nervous system of the rat *Neuroscience* 1 349-351, 1976
- 4 Esposito, R U, T Perry and C Kornetsky Effects of D-amphetamine and naloxone on brain stimulation reward Psichopharmacology 69 187-191, 1980
- 5 Franklin, K B J and A Robertson 5HT blockade and the stimulant effects of D- and L-amphetamine No interaction in self-stimulation of prefrontal cortex, hypothalamus, or dorsal tegmentum Unexpected lethality in hippocampal sites *Phar*mac Biochem Behav 13 365-370, 1980
- 6 Goldstein, J M and J B Malick Effect of substance P on medial forebrain bundle self-stimulation in rats following intracerebral administration *Pharmac Biochem Behav* 7 475-478, 1977
- 7 Heikkila, R E, H Orlanski, C Mytilineou and G Cohen Amphetamine evaluation of D- and L-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex J Pharmac exp. Ther 194 47-56, 1975
- 8 Holmes, J C and C A Rutledge Effects of the D- and L-isomers of amphetamine on uptake release and catabolism of norepinephrine, dopamine, and 5-hydroxytryptamine in several regions of rat brain *Biochem Pharmac* 25 447-451 1976
- 9 Holtzman, S G Comparison of the effects of morphine, pentazocine, cyclazocine and amphetamine on intracranial selfstimulation in the rat *Psychopharmacologia* 46 223-227, 1976
- 10 Hughes, J., T. W. Smith, H. W. Kosterlitz, L. A. Fothergill, B. A. Morgan and H. R. Morris. Identification of two related pentapeptides from the brain with potent opiate agonist activity *Nature* 258 577-579, 1975

- 11 Lal, H Narcotic dependence, narcotic action and dopamine receptors Life Sci 17 483-496 1975
- 12 Lorens S A and S M Sainati Naloxone blocks the excitatory effect of ethanol and chlordiazepoxide on lateral hypothalamic self-stimulation behavior *Life Sci* 23 1359–1364 1978
- 13 Pellegrino L J and A J Cushman A Stereotaxic Atlas of the Rat Brain 1st edition New York Appleton-Century-Crofts, 1967
- 14 Phillips A G and H C Fibiger Dopaminergic and noradrenergic substrates of positive reinforcement Differential effects of d- and l-amphetamine Science 179 575-576 1973
- 15 Pollard, H C Lorens J C Schwartz, C Gros and F Dray Localization of opiate receptors and enkephalins in the rat striatum in relationship with the nigrostriatal dopaminergic system lesions studies *Brain Res* 151 392–398, 1978
- 16 Simantov, R M J Kuhar G W Pasternak and S H Snyder The regional distribution of a morphine-like factor enkephalin in monkey brain Brain Res 106 189–197 1976
- 17 Simantov R, M J Kuhar, G R Uhl and S H Snyder Opioid peptide enkephalin Immunohistochemical mapping in rat central nervous system *Proc natn Acad Sci U S A* 74 2167– 2171 1977
- 18 Snyder, S H Opiate receptor in normal and drug altered brain function Nature 257 185-189, 1975
- 19 Stapleton J M V J Merriman C L Coogle, S D Gelbard and L D Reid Naloxone reduces pressing for intracranial stimulation of sites in the periaqueductal gray area accumbens nucleus substantia nigra and lateral hypothalamus *Physiol Psychol* 7 427-436 1979
- 20 Van der Kooy D, F C LePiane and A G Phillips Apparent independence of opiate reinforcement and electrical selfstimulation systems in rat brain *Life Sci* **20** 981–986, 1977
- 21 Wauquier, A C J F Niemegeers and H Lal Differential antagonism by naloxone of inhibitory effects of haloperidol and morphine on brain self-stimulation *Psychopharmacologia* 37 303-310, 1974